Financials in USD. Standardized financial statements.
A compact view of how Xilio Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|
| Revenue? | $43.77M | $6.34M | $0 | $0 | $0 | $0 | $0 |
| Revenue Growth? | +589.9% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Cost of Revenue? | $1.54M | $0 | $0 | $0 | $1.50M | $1.06M | $240,000 |
| Gross Profit? | $42.23M | $6.34M | $0 | $0 | -$1.50M | -$1.06M | -$240,000 |
| Gross Margin? | +96.5% | +100.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses? | $84.21M | $66.93M | $79.13M | $89.15M | $73.55M | $53.50M | $18.79M |
| Operating Income? | -$41.98M | -$60.58M | -$79.13M | -$89.15M | -$75.04M | -$54.56M | -$19.03M |
| EBITDA? | -$40.44M | -$58.00M | -$77.23M | -$87.30M | -$73.70M | -$53.55M | -$17.07M |
| Income Before Tax | -$35.04M | -$58.24M | -$76.40M | -$88.22M | -$75.80M | -$55.22M | -$17.31M |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income? | -$35.04M | -$58.24M | -$76.40M | -$88.22M | -$75.80M | -$55.22M | -$17.31M |
| EPS? | $-4.19 | $-15.26 | $-38.92 | $-45.08 | $-189.28 | $-1475.88 | $-592.06 |
| Diluted EPS? | $-4.19 | $-15.26 | $-38.92 | $-45.08 | $-189.28 | $-1475.88 | $-592.06 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality